MERIDIAN BIOSCIENCE INC 10-Q

Reportable Segment and Major Customers Information (Tables)

3 Months Ended

Dec. 31, 2022

Reportable segment and corporate information for the interim periods is as follows:


	Diagnostics			Life Science		Corporate (1)			Eliminations (2)			Total
Three Months Ended December 31, 2022
Net revenues -
Third-party	$	39,366		$	17,536	$	—		$	—		$	56,902
Inter-segment		86			8		—			(94	)		—
Operating income (loss)		3,160			5,383		(36,693	)		35			(28,115	)
Goodwill (December 31, 2022)		94,432			26,135		—			—			120,567
Other intangible assets, net (December 31, 2022)		71,570			2		—			—			71,572
Total assets (December 31, 2022)		353,997			102,775		—			(9	)		456,763

Three Months Ended December 31, 2021
Net revenues -
Third-party	$	33,204		$	55,137	$	—		$	—		$	88,341
Inter-segment		34			55		—			(89	)		—
Operating income (loss)		(1,763	)		26,602		(4,571	)		15			20,283
Goodwill (September 30, 2022)		94,412			21,890		—			—			116,302
Other intangible assets, net (September 30, 2022)		74,129			2		—			—			74,131
Total assets (September 30, 2022)		357,630			105,511		—			(44	)		463,097

(1)	Includes acquisition and transaction related costs and litigation and select legal costs of $34,048 and $281 in the three months ended December 31, 2022 and 2021, respectively.

(2)	Eliminations consist of inter-segment transactions.

Pre-tax Earnings Table

A reconciliation of reportable segment operating income (loss) to consolidated earnings

(loss)

before income taxes is as follows:


Three Months Ended December 31,	2022			2021
Operating income (loss):
Diagnostics segment	$	3,160		$	(1,763)
Life Science segment		5,383			26,602
Eliminations		35			15

Total operating income		8,578			24,854
Corporate expenses		(36,693	)		(4,571	)
Interest income		3			1
Interest expense		(148	)		(372	)
Other, net		(837	)		(161	)

Consolidated earnings (loss) before income taxes	$	(29,097	)	$	19,751

Consolidated Net Revenues

Three individual Diagnostics and two Life Science segment customers, including their affiliates, comprising 10% or more of reportable segment net revenues were as follows:


Three Months Ended December 31,	2022			2021

Diagnostics
Customer A		7	%		10	%
Customer B		10	%		11	%
Customer C		12	%		11	%
Life Science
Customer D		—	%		23	%
Customer E		4	%		14	%
Customer F		12	%		5	%

In addition,

one of

the Life Science segment customers, including their affiliates, identified above accounted for greater than 10% of consolidated net revenues as follows:

Three Months Ended December 31,

Life Science

Customer D